無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のiPS細胞 (人工多能性幹細胞) 産業調査:2018-2019年

Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report 2019

発行 BIOINFORMANT WORLDWIDE, LLC 商品コード 250774
出版日 ページ情報 英文 145 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.44円で換算しております。
Back to Top
世界のiPS細胞 (人工多能性幹細胞) 産業調査:2018-2019年 Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report 2019
出版日: 2019年01月31日 ページ情報: 英文 145 Pages
担当者のコメント
iPS細胞に着目した市場トレンドをまとめた、待望のレポートがBIOINFORMANT 社よりリリースされました。米国や日本などiPS細胞市場が注目される国をはじめ、地域別市場を、各製品セグメント別(Reprogramming、Cell Culture、Diffeentiationなど)、アプリケーション別(Academic, Stem cell biobankingなど)にまとめております。注目の技術トレンドの解説や参入企業、製品プロファイルもカバーしております。
概要

当レポートでは、世界のiPS細胞産業について調査し、市場規模、製品分類・用途・地域別による市場分析、5ヵ年の市場予測、補助金・治験・科学出版物のトレンド分析、特許・IP環境の分析、SWOT分析、および市場リーダーの競合分析・企業プロファイルなどをまとめています。

調査範囲・手法

エグゼクティブサマリー

背景 - iPSC (iPS細胞) 研究

  • iPSCについて
  • iPSC研究・用途の進化
  • iPSCの科学的発見・発見以来の進歩
  • iPSCの将来利用の可能性
  • 現在の活用
  • 最新研究アップデート
  • iPSCのメリット・デメリット
  • 企業による近年の活動

市場分析:製品分類

  • 市場区分
  • 主な調査結果
  • イントロダクション
  • リプログラミング
  • 細胞培養
  • 差別化
  • 細胞分析
  • エンジニアリング
  • その他

市場分析:用途別

  • 市場区分
  • 主な調査結果
  • 学術研究
  • 創薬
  • 細胞療法
  • 薬物中毒のスクリーニング検査
  • 幹細胞バイオバンキング

市場分析:地域別

  • 市場区分
  • 主な調査結果
  • 北米
  • 欧州
  • アジア太平洋
  • その他

特許

  • 主な調査結果
  • イントロダクション
  • 特許リスト
  • 特許:地域別
  • 特許:分類別

企業別

  • iPSCの競合情勢

企業プロファイル

結論

目次

Stem cell research and experimentation have been in process for well over five decades, as stem cells have the unique ability to divide and replicate repeatedly. In addition, their “unspecialized” nature allows them to differentiate into a wide variety of specialized cell types. The possibilities arising from these characteristics have resulted in great commercial interest, with potential applications including basic research, cell therapeutics, tissue regeneration, pharmacological testing on cell-specific tissues, personalized medicine and more.

Traditionally, scientists have worked with both embryonic and adult stem cells. While the appeal of embryonic stem cells is their ability to differentiate into any type of cell, there is significant ethical, moral, and spiritual controversy surrounding their use. Although adult stem cells do have differentiation capacity, it is often limited in nature, which results in fewer options for use.

Groundbreaking experimentation in 2006 led to the introduction of induced pluripotent stem cells (iPSCs). These are adult cells which are isolated and then transformed into embryonic-like stem cells through the manipulation of gene expression or other methods. Research and experimentation using mouse cells by Shinya Yamanaka's lab at Kyoto University in Japan was the first instance in which there was successful generation of iPSCs. In 2007, a series of follow-up experiments was done at Kyoto University in which human cells were transformed into iPSCs. Nearly simultaneously, a research group led by James Thomson at the University of Wisconsin-Madison accomplished the same feat of deriving iPSC lines from human somatic cells.

Since the discovery of iPSCs a large and thriving research product market has grown into existence, largely because the cells are non-controversial and can be generated directly from adult cells.

Market for iPSCs

The market for iPS cell therapies is rapidly expanding, with Cynata Therapeutics recently completing the world's first Phase I trial with an iPSC-derived therapeutic product (CYP-001). In January 2017, FUJIFILM took a strategic equity stake in Cynata Therapeutics of 9%, for which it paid A$3.97 million. Under the agreement, the parties are collaborating on the development and commercialisation CYP-001 for graft-versus-host disease (GvHD).

Additionally, Fate Therapeutics is positioned to launch the world's first trial with an iPSC-derived therapeutic product within the United States, following the FDA's November 2018 approval of its IND Application for FT500. FT500 is a universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line.

There are also numerous physician-led studies underway in Japan exploring the use of iPSC-derived therapies for the treatment of macular degeneration, Parkinson's disease, heart disease, and the production of human platelets.

In addition to these therapeutic advances, recent years have seen advances in drug development and discovery, as iPSCs have the potential to transform drug discovery by providing physiologically relevant cells for compound identification, target validation, compound screening, and tool discovery. iPSCs are also valuable for toxicology screening, which is the use of stem cells or their derivatives (tissue-specific cells) to assess the safety of compounds or drugs within living cells. Finally, growing numbers of iPSC banks are providing researchers with iPSC-derived cell types from both healthy and diseased donors.

iPSC Market Breakdown

As shown in the image below, the iPSC market can be segmented into three primary categories (Product Category, Commercial Application, and Geography), as well as sub-segmented into a total of 15 different market categories.

This global strategic report presents market size estimations for each of these 15 segments, accompanied by 5-year projections. It also presents an aggregated value for the global iPSC marketplace.

The dominant company within the iPSC market is FUJIFILM Cellular Dynamics, Inc. (FCDI). Headquartered in Madison, Wisconsin, Cellular Dynamics International (CDI) was founded by Dr. James Thomson, who derived iPSC lines from human somatic cells in 2007. Now owned by Fujifilm, CDI is the world's largest manufacturer of human iPSCs. Another early market competitor was ReproCELL, a company established in 2009 as a venture company originating from the University of Tokyo and Kyoto University.

A European leader within the iPSC market is Ncardia, formed through the merger of Axiogenesis and Pluriomics in 2017. After Yamanaka's groundbreaking iPSC technology became available, Axiogenesis was the first European company to license it in 2010. Today, Ncardia's focus is on preclinical drug discovery and drug safety through the development of functional assays using human neuronal and cardiac cells, although it is expanding into new areas. Its flagship offering is its Cor.4U human cardiomyocyte product family, including cardiac fibroblasts.

Based in the UK, Axol Bioscience also specializes in iPSC-derived cells, disease models, human primary cells and culture media optimized for pluripotent stem cell growth. Dozens of other market competitors also offer innovative iPSC products and services.

Key report findings include:

  • Market Size Determination for the Global iPSC Market
  • Market Segmentation by Product Category, Application, and Geography
  • Five-Year Market Size Projecitons
  • Trend Analysis for iPSC Grants, Trials, and Scientific Publications
  • Analysis of iPSC Patent Environment, including Key Patents and Assignees
  • SWOT Analysis for the iPSC Market (Strengths, Weaknesses, Opportunities, Threats)
  • Review of Clinical Progress with iPSCs
  • Competitive Analysis of iPSC Market Leaders
  • Review of iPSC Product and Service Offerings
  • And Much More

iPSC Report Inputs

In addition to extensive secondary research performed by BioInformant's team of analysts, telephone interviews were conducted with key industry leaders, including Kaz Hirao (President and COO of Fujifilm Cellular Dynamics), Robin Smith (CEO of ORIG3N), Dr. Ross Macdonald (CEO of Cynata Therapeutics), Dr. Paul Wotton (Board Member of Cynata Therapeutics), and others.

In summary, iPSCs represent a promising tool for use in the reversal and repair of many previously incurable diseases. To profit from this lucrative and rapidly expanding market, you need to understand your key strengths relative to the competition, intelligently position your products to fill gaps in the market place, and take advantage of crucial iPSC trends.

Table of Contents

SCOPE AND METHODOLOGY

  • Market Definition
  • Market Scope
  • Market Stakeholders
  • Research Methodology
    • Secondary and Primary Research Methodology
  • Market Size Estimation Methodology
  • Market Forecast Methodology
    • Assumptions
    • Years Considered for the Study
    • Currency

EXECUTIVE SUMMARY

  • Introduction

BACKGROUND - iPSC RESEARCH

  • About iPSCs
    • Importance of iPSCs in Modern Medical Science
  • Evolution of iPSC Research and Application
  • Scientific Discoveries and Progress Since Discovery of iPSCs
  • Potential Future Use of iPSCs
    • Hepatic Differentiation of Human iPSCs
    • Disease Modelling with Human iPSCs
    • Drug Toxicity and Drug Discovery using Human iPSCs
    • Therapeutic Potential of Human iPSCs
  • Present Day Utilizations
    • Drug Development and Discoveries
    • Cellular Therapy
    • Toxicology Screening
    • iPSC Cell Lines and iPSC Banks
    • Cancer Research
  • Recent Research & Clinical Updates
    • Building the World's Largest iPSC Repository
    • 1st Investigator Led Study with iPSC-derived Cell Sheets to Treat Macular Degeneration (RIKEN)
    • World's 1st Clinical Trial with Allogeneic iPSC-Derived Therapeutic Product (Cynata Therapeutics)
    • Physician Led Study Using iPSCs for Parkinson's Disease (Kyoto University)
    • Physician Led Study Using iPSC-derived Cell Sheets for Heart Disease (Osaka University)
    • Moving iPSC-derived Platelets Toward the Clinic (CiRA of Kyoto University)
  • Advantages and Disadvantages of iPSC
    • Advantages of iPSCs
    • Disadvantages of iPSCs
  • Recent Activity: iPSC Research Supply Companies
    • Ncardia and Nanion Technologies
    • FUJFILM Cellular Dynamics and University of California - Irvine
    • Evotec and Celgene
    • Ncardia (Formed by Merger of Pluriomics and Axiogenesis)
    • Pharma and Axol Bioscience
    • Evotec and Censo Biotechnologies
    • ORIG3N
    • Fujifilm Establishes CDI Japan
    • Stemgent Company
    • Fujifilm Holdings
    • REPROCELL
  • Recent Activity: iPSC Cell Therapy Companies / Organizations
    • Fate Therapeutics and ONO Pharmaceutical
    • Cynata Therapeutics (Positive Phase I Data)
    • Center for iPS Cell Research & Application (CiRA), Kyoto University
    • Osaka University
    • Fujifilm and Takeda Pharmaceutical
    • BlueRock Therapeutics and Universal Cells
    • RIKEN
    • Fujifilm Takes Equity Stake in Cynata Therapeutics
    • Cellular Dynamics International (CDI)
    • RIKEN Centre for Developmental Biology (CDB)

MARKET ANALYSIS BY PRODUCT CATEGORY

  • Market Segments
  • Key Findings
  • Introduction
  • Reprogramming
  • Cell Culture
  • Differentiation
  • Cell Analysis
  • Engineering
  • Others

MARKET ANALYSIS BY APPLICATION

  • Key Findings
  • Introduction
  • Academic Research
  • Drug Development & Discovery
  • Cellular Therapy
  • Toxicology Screening
  • Stem Cell Banking

MARKET ANALYSIS BY GEOGRAPHY

  • Key Findings
  • Introduction
  • North America
  • Europe
  • APAC
  • Rest of the World (ROW)

SCIENTIFIC PUBLICATIONS

  • Key Findings
  • Overview of iPSC Research Activity

PATENTS

  • Key Findings
  • Introduction
  • Patent List
  • Patents by Geography
    • Commentary
  • Patents by Category
    • Commentary

ANALYSIS OF iPSC MARKET LEADERS

  • FEATURED COMPANIES: Companies Specializing in iPSC Products
    • Cellular Dynamics International (CDI), a Fujifilm Company
    • Ncardia
    • REPROCELL
    • Axol Bioscience
  • FEATURED COMPANIES: Broad Providers of Research Tools to Include iPSC Products
    • Lonza
    • Thermo Fisher Scientific
    • Takara Bio
  • FEATURED COMPANIES: Companies Developing iPSC-Derived Cell Therapeutics
    • Cynata Therapeutics
    • Fate Therapeutics
    • Megakaryon Corporation
    • RIKEN
    • ORIG3N

CONCLUSIONS

List of Figures

  • Figure 1: Research Methodology Steps
  • Figure 2: Market Size Estimation Methodology: Bottom-Up Approach
  • Figure 3: Market Size Estimation Methodology: Top-Down Approach
  • Figure 4: Research Design
  • Figure 5: Global Induced Pluripotent Stem Cell Market Estimates - 2017-2022 (USD billion)
  • Figure 6: Process of iPSC Cell Formation
  • Figure 7: From Somatic Cell to Treatment
  • Figure 8: The Leading Applications for Pluripotent Stem Cell Derivatives
  • Figure 9: iPS Derived Models of Diabetic Cardiomyopathy
  • Figure 10: Recent Technological Updates and Clinical Applications of Induced Pluripotent Stem Cells
  • Figure 11: iPSC Technology
  • Figure 12: Human Induced Pluripotent Stem Cell (hiPSC)-based Platforms for Drug Development
  • Figure 13: Construction of Carcinogenesis model
  • Figure 14: iPSCs in Dentistry
  • Figure 15: Stem Cell Reprogramming
  • Figure 16: Bad effects of iPSCs
  • Figure 17: iPSC market Share by Product Type
  • Figure 18: Share of of iPSC Clinical Studies by Region (January 2015 to August 2017)
  • Figure 19: Percentage Share of Patent Granted by Region (2012-2017)
  • Figure 20: Percentage Share of Patents by Categories (2012-2017)

List of Tables

  • Table 1: From Innovation to Commercialization
  • Table 2: Global iPSC Market, by Product Category, USD Million, 2015 - 2022
  • Table 3: Global iPSC Reprogramming Market, by Geography, USD Million, 2015 - 2022
  • Table 4: Global iPSC Cell Culture Market, by Geography, USD Million, 2015 - 2022
  • Table 5: Global iPSC Differentiation Market, by Geography, USD Million, 2015 - 2022
  • Table 6: Global iPSC Cell Analysis Market, by Geography, USD Million, 2015 - 2022
  • Table 7: Global iPSC Engineering Market, by Geography, USD Million, 2015 - 2022
  • Table 8: Global iPSC Other Product Category Market, by Geography, USD Million, 2015 - 2022
  • Table 9: Global iPSC Market, by Application, USD Million, 2015 - 2022
  • Table 10: Global iPSC Market for Academic Research Application, by Geography, USD Million, 2015 - 2022
  • Table 11: Global iPSC Market for Drug Development & Discovery Application, by Geography, USD Million, 2015 - 2022
  • Table 12: Global iPSC Market for Cellular Therapy Application, by Geography, USD Million, 2015 - 2022
  • Table 13: Global iPSC Market for Toxicology Screening Application, by Geography, USD Million, 2015 - 2022
  • Table 14: Global iPSC Market for Stem Cell Biobanking, by Geography, USD Million, 2015 - 2022
  • Table 15: iPSC Publication Output, Growth and Citation Impact, by Country (2008 to 2012)
  • Table 16: Global iPSC Market, by Geography, USD Million, 2015 - 2022
  • Table 17: North America iPSC Market for Academic Research Application, by Country, USD Million, 2015 - 2022
  • Table 18: North America iPSC Market, by Product Category, USD Million, 2015 - 2022
  • Table 19: North America iPSC Market, by Application, USD Million, 2015 - 2022
  • Table 20: U.S. iPSC Market, by Product Category, USD Million, 2015 - 2022
  • Table 21: U.S. iPSC Market, by Application, USD Million, 2015 - 2022
  • Table 22: Europe iPSC Market, by Product Category, USD Million, 2015 - 2022
  • Table 23: Europe iPSC Market, by Application, USD Million, 2015 - 2022
  • Table 24: APAC iPSC Market for Academic Research Application, by Country, USD Million, 2015 - 2022
  • Table 25: APAC iPSC Market, by Product Category, USD Million, 2015 - 2022
  • Table 26: APAC iPSC Market, by Application, USD Million, 2015 - 2022
  • Table 27: Japan iPSC Market, by Product Category, USD Million, 2015 - 2022
  • Table 28: Japan iPSC Market, by Application, USD Million, 2015 - 2022
  • Table 29: RoW iPSC Market, by Product Category, USD Million, 2015 - 2022
  • Table 30: RoW iPSC Market, by Application, USD Million, 2015 - 2022
Back to Top